Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases

References

• Lee TW, Fedorak RN. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am. 2010;39(3):543–557.
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Ylikyla S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology. 2017;56(5):725–735.
   PubMedGoogle Scholar
• Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity. 2014;47(2):77–94.
   PubMed Web of Science ®Google Scholar
• Joensuu JT, Aaltonen KJ, Aronen P, et al. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a register study. Rheumatology. 2016;55(10):1803–1811.
   PubMed Web of Science ®Google Scholar
• Chima M, Lebwohl M. TNF inhibitors for psoriasis. Semin Cutan Med Surg. 2018;37(3):134–142.
   PubMed Web of Science ®Google Scholar
• Kurz K, Herold M, Winkler C, et al. Effects of adalimumab therapy on disease activity and interferon-gamma-mediated biochemical pathways in patients with rheumatoid arthritis. Autoimmunity. 2011;44(3):235–242.
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLOS One. 2012;7(1):e30275.
   PubMed Web of Science ®Google Scholar
• Sozzani S, Abbracchio MP, Annese V, et al. Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity. 2014;47(5):287–306.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Petroni G, Pratesi S, et al. How the immune system responds to therapeutic biological agents. J Int Med Res. 2016;44(1 suppl):38–42.
   PubMedGoogle Scholar
• Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215–226.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Borghi A, Meroni PL, et al. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity. 2014;47(3):146–153.
   PubMed Web of Science ®Google Scholar
• Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63(2):359–364.
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Gardette A, Tubach F, et al. Body mass index and response to infliximab in rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(4):478–483.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2009;2(4):245–251.
   PubMedGoogle Scholar
• Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36(10):2171–2177.
   PubMedGoogle Scholar
• Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247–2259.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7(4):289–300.
   PubMed Web of Science ®Google Scholar
• Anttila Veli-Jukka HJ, Ritva P, Tarja T-K, et al. Biologisten lääkkeiden tauotus tulehduksellisia tauteja sairastavilla [Discontinuation of biological drugs in patients with inflammatory diseases]. Duodecim. 2016;132:369–376.
   PubMedGoogle Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. Inflamm Bowel Dis. 2019;25(4):627–641.
   PubMedGoogle Scholar
• Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–1254.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56(9):1226–1231.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33(9):987–995.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marin AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016;111(5):632–647.
   PubMed Web of Science ®Google Scholar
• Wolf D, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons. Clin Ther. 2017;39(4):849–862.e846.
   PubMed Web of Science ®Google Scholar
• Janssen Biologics B.V. Remicade, Prescribing information. European Medicines Agency; 2020. [cited 2021 Aug 8]. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf.
   Google Scholar
• AbbVie Biotechnology GmbH. Humira, Precribing Information; 2021. [cited 2021 Aug 8]. Available from: https://www.rxabbvie.com/pdf/humira.pdf.
   Google Scholar
• Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879–913.
   PubMed Web of Science ®Google Scholar
• Titton DC, Silveira IG, Louzada-Junior P, et al. Brazilian biologic registry: Biobada Brasil implementation process and preliminary results. Rev Bras Reumatol. 2011;51(2):152–160.
   PubMedGoogle Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50(1):124–131.
   PubMed Web of Science ®Google Scholar
• Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18(1):71.
   PubMedGoogle Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601–608.
   PubMed Web of Science ®Google Scholar
• Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017;35:1043–1046.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Virkki LM, Valleala H, Takakubo Y, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30(11):1447–1454.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Szabo MZ, Kedves M, et al. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18(12):102398.
   PubMedGoogle Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468.
   PubMed Web of Science ®Google Scholar
• Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: case series and review of literature. World J Gastrointest Pharmacol Ther. 2017;8(3):155–161.
   PubMedGoogle Scholar
• Finnish Institute for Health and Welfare. Reumalääkityksen tauottaminen tai vähentäminen [Dosage reduction and discontinuation of rheumatic medication]. 2019. [cited 2021 Jan 3]. Available from: https://thl.fi/fi/web/infektiotaudit-ja-rokotukset/tietoa-rokotuksista/eri-kohderyhmien-rokottaminen/laaketieteellisten-riskiryhmien-rokottaminen/reumatauteja-sairastavien-aikuisten-rokottaminen/reumalaakityksen-tauottaminen-tai-vahentaminen.
   Google Scholar
• Puchner A, Grochenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation: a consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr. 2019;131(1–2):29–44.
   PubMed Web of Science ®Google Scholar